Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Journal of Managed Care & Specialty Pharmacy|August 24, 2022
Characterizing health plan evidence review practicesAri D Panzer, Daniel E Enright, Jen Graff, et al.The American Journal of Managed Care|September 20, 2023
Varied use of step therapy among Medicare Advantage plansNola B Jenkins, Donald E Nichols, Daniel E Enright, et al.Journal of Managed Care & Specialty Pharmacy|February 28, 2025
Use of health technology assessments in specialty drug coverage decisions by US commercial health plansDaniel E Enright, Emma G van Duijnhoven, Daniel A Ollendorf, et al.Applied Health Economics and Health Policy|December 18, 2022
The Value of New: Consideration of Product Novelty in Health Technology Assessments of PharmaceuticalsPatricia G Synnott, Dominic Voehler, Daniel E Enright, et al.Pharmacoeconomics|October 26, 2021
Is an Orphan Drug's Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?James D Chambers, Nikoletta M Margaretos, Daniel E Enright, et al.Applied Health Economics and Health Policy|September 3, 2024
Are Drug Novelty Characteristics Associated With Greater Health Benefits?A Alex Levine, Daniel E Enright, Katherine A Clifford, et al.Pharmacoepidemiology and Drug Safety|March 27, 2020
What types of real-world evidence studies do U.S. commercial health plans cite in their specialty drug coverage decisions?Ari D Panzer, Nikoletta M Margaretos, Rachel C Lai, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 2, 2024
The Health Benefits, Costs, and Cost-Effectiveness of Ultraorphan DrugsKatherine A Clifford, A Alex Levine, Daniel E Enright, et al.Health Affairs (Project Hope)|November 4, 2024
Small-Molecule Drugs Offer Comparable Health Benefits To Biologics At Lower CostsKatherine A Clifford, A Alex Levine, Daniel E Enright, et al.Health Affairs Scholar|May 17, 2024
Commercial coverage of specialty drugs, 2017-2021Julia A Rucker, Molly T Beinfeld, Nola B Jenkins, et al.Pageof 2